Pfizer Inc. (PFE) Position Lifted by Monarch Capital Management Inc.

Monarch Capital Management Inc. raised its position in shares of Pfizer Inc. (NYSE:PFE) by 3.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 131,056 shares of the biopharmaceutical company’s stock after buying an additional 4,150 shares during the quarter. Pfizer accounts for 1.7% of Monarch Capital Management Inc.’s portfolio, making the stock its 25th largest position. Monarch Capital Management Inc.’s holdings in Pfizer were worth $4,679,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of PFE. Janus Henderson Group PLC lifted its position in shares of Pfizer by 243.5% in the second quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock worth $442,574,000 after purchasing an additional 9,339,749 shares in the last quarter. Vanguard Group Inc. raised its position in Pfizer by 2.3% during the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after acquiring an additional 9,239,499 shares in the last quarter. Renaissance Technologies LLC bought a new position in Pfizer during the second quarter valued at approximately $268,389,000. Canada Pension Plan Investment Board raised its position in Pfizer by 249.6% during the second quarter. Canada Pension Plan Investment Board now owns 10,713,626 shares of the biopharmaceutical company’s stock valued at $359,871,000 after acquiring an additional 7,649,416 shares in the last quarter. Finally, Parametric Portfolio Associates LLC raised its position in Pfizer by 42.1% during the second quarter. Parametric Portfolio Associates LLC now owns 17,818,368 shares of the biopharmaceutical company’s stock valued at $598,519,000 after acquiring an additional 5,281,314 shares in the last quarter. 69.74% of the stock is owned by institutional investors.

PFE has been the topic of several recent research reports. Vetr lowered shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price objective on the stock. in a research report on Wednesday, September 13th. BMO Capital Markets reiterated a “buy” rating and set a $37.00 price target on shares of Pfizer in a report on Thursday, September 14th. Jefferies Group set a $37.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research note on Monday, September 18th. Sanford C. Bernstein set a $39.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Tuesday, September 19th. Finally, Morgan Stanley upgraded shares of Pfizer from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $35.00 to $39.00 in a research note on Wednesday, September 20th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $38.83.

Pfizer Inc. (PFE) traded up $0.09 during trading on Thursday, hitting $36.56. The company had a trading volume of 14,311,800 shares, compared to its average volume of 15,770,000. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. The company has a market capitalization of $217,920.00, a PE ratio of 22.43, a price-to-earnings-growth ratio of 2.46 and a beta of 1.01. Pfizer Inc. has a fifty-two week low of $30.90 and a fifty-two week high of $37.35.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. The firm had revenue of $13.17 billion during the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The company’s revenue was up .9% on a year-over-year basis. During the same period last year, the company earned $0.61 earnings per share. equities analysts predict that Pfizer Inc. will post 2.59 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be given a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 3.72%. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date of this dividend is Thursday, February 1st. Pfizer’s dividend payout ratio (DPR) is presently 78.53%.

Pfizer announced that its board has approved a stock buyback plan on Monday, December 18th that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the biopharmaceutical company to buy shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its stock is undervalued.

In related news, insider Alexander R. Mackenzie sold 6,750 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the transaction, the insider now directly owns 103,458 shares in the company, valued at approximately $3,827,946. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Rady A. Johnson sold 8,000 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.07, for a total value of $296,560.00. Following the completion of the transaction, the executive vice president now owns 46,963 shares of the company’s stock, valued at $1,740,918.41. The disclosure for this sale can be found here. Over the last quarter, insiders sold 29,450 shares of company stock valued at $1,065,220. Corporate insiders own 0.06% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/11/monarch-capital-management-inc-has-4-68-million-holdings-in-pfizer-inc-pfe.html.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply